Using pharmacogenetics to personalize treatment outcome to ranibizumab (Lucentis) for the eye disease age-related macular degeneration (AMD)

利用药物遗传学使雷珠单抗（Lucentis）治疗眼病年龄相关性黄斑变性（AMD）的结果个性化

• 批准号: nhmrc : 1008979
• 负责人: Prof Paul Baird
• 金额: $ 41.6万
• 依托单位: Centre for Eye Research Australia Ltd
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/using-pharmacogenetics-personalize-degeneration-amd/109362
• 关键词: Using; pharmacogenetics; personalize; treatment; outcome

The drug Lucentis has revolutionized the treatment of age-related macular degeneration, one of the commonest causes of severe vision loss in Australia. Unfortunately, up to 25% of patients continue to lose vision despite this treatment. We will use the latest gene chip technology to identify the genetic variant responsible for this poor response. Having this information will allow us to personalise treatment for the patient leading to improvement in their vision.

药物Lucentis彻底改变了年龄相关性黄斑变性的治疗，这是澳大利亚严重视力丧失的最常见原因之一。不幸的是，高达25%的患者继续失去视力，尽管这种治疗。我们将使用最新的基因芯片技术来识别导致这种不良反应的遗传变异。拥有这些信息将使我们能够为患者提供个性化治疗，从而改善他们的视力。